Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on June 25, 2012. The filing discloses a significant executive appointment within the company's leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Stefan K.F. Schwabe, MD, Ph.D., as Executive Vice-President Research & Development and Chief Medical Officer. Dr. Schwabe is scheduled to join the company on or about July 9, 2012.
Management Commentary and Compensation Details
Dr. Schwabe brings over 20 years of experience in developing central nervous system (CNS) pharmaceutical products, with prior leadership roles at DemeRx, Sanofi-Aventis, Novartis, Johnson & Johnson, and Novo Nordisk. His compensation package includes:
- Base Salary: $320,000 annually.
- Bonus: Eligible for an annual target bonus of up to 25% of base salary, prorated for the first year and contingent on performance.
- Equity: An award of 95,000 stock options subject to Board approval, vesting over four years.
- Relocation: Reimbursement for travel and residence rental expenses up to $85,000 in aggregate, spread over the first five years of employment.
Investor Verification Checklist
- Confirm the start date of Dr. Schwabe's employment (expected July 9, 2012).
- Verify the Board of Directors' approval of the 95,000 stock option grant.
- Review the specific performance metrics tied to the annual bonus plan.
- Assess the impact of the $85,000 relocation expense cap on future cash flow.